INTRODUCTION
Breast cancer is the most common diagnosed malignancy in women worldwide (22%) and in India (18.5%) it ranks second to cervical cancer. The burden of breast cancer is increasing in both developed and developing countries; the peak occurrence of breast cancer in developed countries is above the age of 50 whereas in India it is above the age of 40. 1 Prognosis of Breast cancer depends on evaluation of various parameters like tumour histological grading, cell proliferation index, oestrogen receptor status and lymph node status is of growing interest. 2 The diagnosis of breast cancer at an earlier stage allows a woman more choice in the selection of treatment option. While physical examination and mammography are useful screening procedures for the early detection of breast cancer, they are also labor intensive and require health professionals who are highly trained and experienced. Nowadays, immuno-histochemistry and serum tumour marker detection is widely used in evaluation in case of breast carcinoma. Tumor markers may be used in diagnosis (early detection and differential diagnosis), prognostic evaluation and follow up (therapeutic monitoring). 3 A frequently used staging system is the TNM (tumor, nodes, and metastasis) system given by American Joint Committee on Cancer (AJCC) demonstrated that tumor size correlates with the presence of axillary lymph node metastases.
CA 15-3 is a mucin belonging to a large family of glycoprotein's encoded by the MUC1 gene. Elevated preoperative CA 15-3 level is directly related to tumour burden and independent prognostic factors for breast cancer. It could be considered for clinical use such as predicting patient outcome and determining adjuvant treatment for better outcome. 5 The 2007 ASCO guidelines state that the routine use of CA 15-3 for screening, diagnosis,staging, or surveillance of breast cancer is not recommended because available data are insufficient. For monitoring patients during active therapy, CA 15-3 can be used in conjunction with diagnostic imaging and history and physical examination CA 15-3 determination is particularly useful in evaluating recurrence of disease and response to treatment. 6 
METHODS
This retrospective study was done on patients in Department Of Surgery, at tertiary care hospital, affiliated to Medical College, from April 2012 to March 2014. Total 30 patients diagnosed with Carcinoma Breast were included in this study. Detailed history and clinical examination was done of all the patients. Routine and Specific investigation (ultrasonography, mammography and FNAC) was sent. Many patients in this study also underwent incisional or excisional biopsy before any treatment for confirmation. Sera samples of all these cases were collected on the day of surgery and sent for preoperative CA 15-3 estimation. Modified radical mastectomy (MRM) with axillary clearance was undertaken and specimen was sent for detailed histological diagnosis. Similarly again after 30 days of surgery patients samples were sent for postoperative CA 15-3 estimation.
In this study no controls were used , but based on other studies of CA 15-3which used controls, normal serum CA 15-3 level was taken as 35 U/mL. Hence in this study also we have taken the normal CA 15-level as 35 U/mL. [7] [8] [9] [10] Blood samples were collected and processed generally within an hour. The samples were centrifuged and stored in multiple tubes at -20°C. The CA 15-3 conjugates reagents prepared by the entire 1ml of conjugate concentrate to 21ml of the enzyme conjugate diluents. Washing buffer was prepared by adding 50 ml of the buffer to 950 ml of distilled water.
All the results of clinical examination, mammography, FNAC and CA 15-3 level before and after surgery were combined and then compared with histopathology examination. The study was approved by the Ethical Committee of the medical college and informed written and verbal consent was obtained from the cases. Serum CA 15-3 concentration was determined by CA 15-3 Enzyme Immunoassay Kit based on the principle of a solid phase enzyme-linked immunosorbent assay (ELISA), purchased from Diametra. Here P value is highly significant. As p value <0.001.
DISCUSSION
In study conducted by Mahindocht et al in 2005 showed number of patients with the malignant breast lesion (6 out of 43) with elevated CA15-3 levels was higher than that in the normal controls (3 out of 39) and patients with benign lesions (1 out of 54). Forty percent of patients in stages II and III had a higher frequency of abnormal CA15-3 values, whereas 13% of those in stage I disease did so. One week after mastectomy, the mean± SD serum CA15-3 was 18.3 ± 14.6 U/mL. However, a month later, the mean±SD was 21.7±19.7 U/mL, which was approximately the same as the preoperative values (mean ± SD: 22.1± 25.6 U/mL). In study conducted by Amina et al average plasma CA 15-3 concentration for breast cancer patients pretreatment has been 54.7 U/mL compare to 24 U/mL for breast cancer patients post-treatment. 4 patients in this study showed an increase in their serum CA 15-3 concentrations more than its primary concentrations before starting therapy. 8 Similar observations were made in studies conducted by Antonella et al found that the mean serum CA 15-3 levels in patients before surgery were significantly higher (36.59 U/ml) compared with those of CA 15-3 after surgery (27.11 U/mL). We also found that elevated preoperative serum levels of CA 15-3 were significantly correlated with the presence of metastatic disease.
In particular, among 305/700 patients (43.6%) that displayed over cut-off (>40 U/mL) preoperative levels of CA 15-3, 94 patients (30, 8%) developed advanced disease (metastases to distant sites). By contrast, in a subgroup of 395/700 patients (56.4%) with CA 15.3 serum levels <40 U/mL, only 32/305 patients (8%) showed signs of advanced disease during follow-up. 9 Hiba et al a statistically significant (p<0.05) increase was noticed in CA15-3 values across breast cancer stages; from stage I to stage III. The preoperative CA15-3 values were significantly higher than the values after three cycles of chemotherapy (p<0.05). 
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